State of the art in anti-cancer mAbs
Following Milstein’s discovery, the monoclonal antibodies (mAbs) became a basic tool for biomedical science. In cancer field, since the first mAb was approved by the FDA a great improvement took place making of them a therapeutic option for many cancer types in the current clinical practice. Today,...
| Autores principales: | , , |
|---|---|
| Formato: | info:ar-repo/semantics/artículo |
| Lenguaje: | Inglés |
| Publicado: |
2017
|
| Materias: | |
| Acceso en línea: | http://hdl.handle.net/20.500.12123/548 https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-016-0311-y https://doi.org/10.1186/s12929-016-0311-y |
| _version_ | 1855034666983096320 |
|---|---|
| author | Chiavenna, Sebastián Matias Jaworski, Juan Pablo Vendrell, Alejandrina |
| author_browse | Chiavenna, Sebastián Matias Jaworski, Juan Pablo Vendrell, Alejandrina |
| author_facet | Chiavenna, Sebastián Matias Jaworski, Juan Pablo Vendrell, Alejandrina |
| author_sort | Chiavenna, Sebastián Matias |
| collection | INTA Digital |
| description | Following Milstein’s discovery, the monoclonal antibodies (mAbs) became a basic tool for biomedical science. In cancer field, since the first mAb was approved by the FDA a great improvement took place making of them a therapeutic option for many cancer types in the current clinical practice. Today, mAbs are being developed to target different molecules with different mechanisms of action and its target potential is unlimited. However, this huge and fast growing new field needs to be organized to better understand the treatment options we have to
confront different cancer diseases. Current cancer targeted immunotherapies aim to achieve different goals like the regulation of osteoclast function, the delivery of cytotoxic drugs into tumor cells and the blockade of oncogenic
pathways, neo-angiogenesis and immune checkpoints. Here, we reviewed the most relevant therapeutic mAbs for solid tumors available in current clinical practice. |
| format | info:ar-repo/semantics/artículo |
| id | INTA548 |
| institution | Instituto Nacional de Tecnología Agropecuaria (INTA -Argentina) |
| language | Inglés |
| publishDate | 2017 |
| publishDateRange | 2017 |
| publishDateSort | 2017 |
| record_format | dspace |
| spelling | INTA5482018-01-12T11:36:07Z State of the art in anti-cancer mAbs Chiavenna, Sebastián Matias Jaworski, Juan Pablo Vendrell, Alejandrina Neoplasmas Anticuerpos Monoclonales Inmunoterapia Neoplasms Monoclonal Antibodies Immunotherapy Cáncer (Enfermedad) Following Milstein’s discovery, the monoclonal antibodies (mAbs) became a basic tool for biomedical science. In cancer field, since the first mAb was approved by the FDA a great improvement took place making of them a therapeutic option for many cancer types in the current clinical practice. Today, mAbs are being developed to target different molecules with different mechanisms of action and its target potential is unlimited. However, this huge and fast growing new field needs to be organized to better understand the treatment options we have to confront different cancer diseases. Current cancer targeted immunotherapies aim to achieve different goals like the regulation of osteoclast function, the delivery of cytotoxic drugs into tumor cells and the blockade of oncogenic pathways, neo-angiogenesis and immune checkpoints. Here, we reviewed the most relevant therapeutic mAbs for solid tumors available in current clinical practice. Instituto de Virología Fil: Chiavenna, Sebastián Matias. Ferrer Advanced Biotherapeutics, Ferrer Internacional; España Fil: Jaworski, Juan Pablo. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina Fil: Vendrell, Alejandrina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro de Estudios Farmacológicos y Botánicos; Argentina. Universidad de Buenos Aires. Facultad de Medicina; Argentina 2017-07-03T15:04:59Z 2017-07-03T15:04:59Z 2017-02-20 info:ar-repo/semantics/artículo info:eu-repo/semantics/publishedVersion info:eu-repo/semantics/article http://hdl.handle.net/20.500.12123/548 https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-016-0311-y 1423-0127 https://doi.org/10.1186/s12929-016-0311-y eng info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by-nc-sa/4.0/ Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) application/pdf Journal of biomedical science (2017) : 24:15 |
| spellingShingle | Neoplasmas Anticuerpos Monoclonales Inmunoterapia Neoplasms Monoclonal Antibodies Immunotherapy Cáncer (Enfermedad) Chiavenna, Sebastián Matias Jaworski, Juan Pablo Vendrell, Alejandrina State of the art in anti-cancer mAbs |
| title | State of the art in anti-cancer mAbs |
| title_full | State of the art in anti-cancer mAbs |
| title_fullStr | State of the art in anti-cancer mAbs |
| title_full_unstemmed | State of the art in anti-cancer mAbs |
| title_short | State of the art in anti-cancer mAbs |
| title_sort | state of the art in anti cancer mabs |
| topic | Neoplasmas Anticuerpos Monoclonales Inmunoterapia Neoplasms Monoclonal Antibodies Immunotherapy Cáncer (Enfermedad) |
| url | http://hdl.handle.net/20.500.12123/548 https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-016-0311-y https://doi.org/10.1186/s12929-016-0311-y |
| work_keys_str_mv | AT chiavennasebastianmatias stateoftheartinanticancermabs AT jaworskijuanpablo stateoftheartinanticancermabs AT vendrellalejandrina stateoftheartinanticancermabs |